The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GYRE | -50.81% | +2.24% | +0.44% | +8% |
| S&P | +18.54% | +92.9% | +14.04% | +61% |
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $26.77M | 6.1% |
| Gross Profit | $25.62M | 4.8% |
| Gross Margin | 95.70% | -1.2% |
| Market Cap | $663.88M | -34.9% |
| Market Cap / Employee | $132.78M | 0.0% |
| Employees | 5 | 0.0% |
| Net Income | $1.58M | -65.3% |
| EBITDA | $2.81M | -19.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $36.49M | 126.7% |
| Accounts Receivable | $25.13M | 34.9% |
| Inventory | 8.9 | 57.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.77M | -40.6% |
| Short Term Debt | $0.62M | -5.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.04% | 0.0% |
| Return On Invested Capital | -90.15% | 19.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.15M | 102.1% |
| Operating Free Cash Flow | $0.41M | 107.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 103.42 | 161.17 | 450.92 | - | |
| Price to Book | 17.02 | 16.43 | 10.52 | 9.46 | -986.41% |
| Price to Sales | 9.83 | 7.82 | 7.39 | - | |
| Price to Tangible Book Value | 17.07 | 16.47 | 10.57 | 10.22 | -1057.88% |
| Enterprise Value to EBITDA | 231.70 | 925.96 | 283.15 | 262.82 | -26.67% |
| Return on Equity | 11.6% | 5.5% | - | ||
| Total Debt | $1.80M | $1.60M | $1.59M | $1.39M | -28.78% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
